Rodenstock Reports FY 2022 Growth and Confirms Sale of Eyewear Business to De Rigo

Rodenstock Group announced solid like-for-like revenue growth of 4% in fiscal year 2022, reaching pro-forma net sales of 505 million euros. The company attributed this performance to demand for its B.I.G. VISION™ biometric progressive lenses and the launch of the B.I.G. NORM™ range. Strategic milestones included the acquisition of Indo Optical in September 2022 and the announced sale of its eyewear business to De Rigo in December 2022, with legal transfer expected in Q2 2023. These moves support Rodenstock’s transformation into a pure-play Med-Tech company focused on lenses. Despite macro-economic headwinds and the exit from the Russian market, recurring EBITDA reached 118 million euros. Leadership changes saw Marcus Desimoni become CEO in February 2023 and Dr. Mani Herold join as CFO in April 2023.